AIRE Is a Critical Spindle-Associated Protein in Embryonic Stem Cells Bin Gu1, Jean-Philippe Lambert2, Katie Cockburn1, Anne-Claude Gingras2,3, Janet Rossant1,3*
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Beacon in Developmental Biology
NEWS Beacon in developmental biology n Cite as: CMAJ 2017 October 16;189:E1298-9. doi: 10.1503/cmaj.109-5460 Posted on cmajnews.com on September 27, 2017. he identification of Gurdon, whom some people the genes responsi- may know recently received ble for controlling the Nobel Prize for his work Tcellular fate and embryonic cloning frogs; undertaking development in mice has research that demonstrates made Dr. Janet Rossant a that all of development is beacon in the field of written in our genes, and all developmental biology. of our cells contain DNA that Her work pioneered tech- has that information, yet niques that allowed genes somehow during develop- to be altered within ment, different genes are embryos. It also acceler- turned on and differentiation ated avenues in the fields occurs. That’s what really of stem cell biology and turned me on to the underly- regenerative medicine. ing problem of ‘how do we She was awarded the get from a fertilized egg to an 2015 Canada Gairdner organism?’ John is the per- Wightman Award, pre- son who really turned me on sented annually to a Cana- to that question and he has dian who has demon- been pursuing it ever since strated outstanding and so have I.” leadership in medicine and medical science. Rossant For the diverse audience was recognized “for her who read CMAJ, can you outstanding contributions explain what stem cells to developmental biology are? and for her exceptional “Stem cells are cells that international leadership in have the ability to self- stem cell biology and pol- renew, make endless copies icy-making, and in advanc- of themselves and yet also ing research programs for retain the potential to differ- children’s illnesses.” Courtesy of Dr. -
The GATA2 Transcription Factor Negatively Regulates the Proliferation of Neuronal Progenitors
RESEARCH ARTICLE 2155 Development 133, 2155-2165 (2006) doi:10.1242/dev.02377 The GATA2 transcription factor negatively regulates the proliferation of neuronal progenitors Abeer El Wakil*, Cédric Francius*,†, Annie Wolff, Jocelyne Pleau-Varet† and Jeannette Nardelli†,§ Postmitotic neurons are produced from a pool of cycling progenitors in an orderly fashion that requires proper spatial and temporal coordination of proliferation, fate determination, differentiation and morphogenesis. This probably relies on complex interplay between mechanisms that control cell cycle, specification and differentiation. In this respect, we have studied the possible implication of GATA2, a transcription factor that is involved in several neuronal specification pathways, in the control of the proliferation of neural progenitors in the embryonic spinal cord. Using gain- and loss-of-function manipulations, we have shown that Gata2 can drive neural progenitors out of the cycle and, to some extent, into differentiation. This correlates with the control of cyclin D1 transcription and of the expression of the p27/Kip1 protein. Interestingly, this functional aspect is not only associated with silencing of the Notch pathway but also appears to be independent of proneural function. Consistently, GATA2 also controls the proliferation capacity of mouse embryonic neuroepithelial cells in culture. Indeed, Gata2 inactivation enhances the proliferation rate in these cells. By contrast, GATA2 overexpression is sufficient to force such cells and neuroblastoma cells to stop dividing but not to drive either type of cell into differentiation. Furthermore, a non-cell autonomous effect of Gata2 expression was observed in vivo as well as in vitro. Hence, our data have provided evidence for the ability of Gata2 to inhibit the proliferation of neural progenitors, and they further suggest that, in this regard, Gata2 can operate independently of neuronal differentiation. -
Stoichiometric and Temporal Requirements of Oct4, Sox2, Klf4, and C-Myc Expression for Efficient Human Ipsc Induction and Differentiation
Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation Eirini P. Papapetroua,b, Mark J. Tomishimac,d, Stuart M. Chambersc, Yvonne Micae, Evan Reeda,b, Jayanthi Menona,f, Viviane Tabara,f, Qianxing Mog, Lorenz Studera,c, and Michel Sadelaina,b,1 aCenter for Cell Engineering, bMolecular Pharmacology and Chemistry and cDevelopmental Biology Programs, dSKI Stem Cell Research Facility, eGerstner Sloan-Kettering Graduate School, and Departments of fNeurosurgery and gEpidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065 Communicated by Mark Ptashne, Memorial Sloan–Kettering Cancer Center, New York, NY, May 1, 2009 (received for review April 8, 2009) Human-induced pluripotent stem cells (hiPSCs) are generated from purposes remains controversial (20). Furthermore, the significance somatic cells by ectopic expression of the 4 reprogramming factors of vector silencing for reprogramming and its impact on differen- (RFs) Oct-4, Sox2, Klf4, and c-Myc. To better define the stoichiometric tiation is unclear. Although it has been proposed that silencing of requirements and dynamic expression patterns required for success- factor expression is required for successful reprogramming and ful hiPSC induction, we generated 4 bicistronic lentiviral vectors multilineage differentiation (3, 21, 22), it remains unclear whether encoding the 4 RFs co-expressed with discernable fluorescent pro- vector silencing constitutes a requirement or an epiphenomenon of teins. Using this system, we define the optimal stoichiometry of RF the reprogramming process. expression to be highly sensitive to Oct4 dosage, and we demonstrate Here we present a vector system for iPSC induction that allows the impact that variations in the relative ratios of RF expression exert for simultaneous real-time tracking of expression of the 4 individual on the efficiency of hiPSC induction. -
Long Noncoding RNA Lncpgcr Mediated by TCF7L2 Regulates Primordial Germ Cell Formation in Chickens
animals Article Long Noncoding RNA LncPGCR Mediated by TCF7L2 Regulates Primordial Germ Cell Formation in Chickens Jingyi Jiang 1, Chen Chen 1, Shaoze Cheng 1, Xia Yuan 1, Jing Jin 1, Chen Zhang 1, Xiaolin Sun 1 , Jiuzhou Song 2 , Qisheng Zuo 1, Yani Zhang 1, Guohong Chen 1 and Bichun Li 1,* 1 Key Laboratory of Animal Breeding Reproduction and Molecular Design for Jiangsu Province, College of Animal Science and Technology, Yangzhou University, Yangzhou 225009, Jiangsu, China; [email protected] (J.J.); [email protected] (C.C.); [email protected] (S.C.); [email protected] (X.Y.); [email protected] (J.J.); [email protected] (C.Z.); [email protected] (X.S.); [email protected] (Q.Z.); [email protected] (Y.Z.); [email protected] (G.C.) 2 Animal & Avian Sciences, University of Maryland, College Park, MD 20741, USA; [email protected] * Correspondence: [email protected] Simple Summary: The potential of primordial germ cells (PGCs) for multidirectional differentiation, together with their unique regeneration ability, makes them one of the most promising seed cells in clinical medicine and tissue engineering research. However, not enough PGCs can be obtained to meet the demand, which limits their application. We defined a novel long noncoding RNA (lncRNA) mediated by epigenetics, which could activate the miR-6577-5p/Btrc pathway to promote the formation of PGCs. The technical system we have established is a useful tool to obtain sufficient PGCs for scientific research. Our study offers great theoretical and practical value in the production of transgenic animals or genomic imprinting in poultry. -
NIH Public Access Author Manuscript Curr Opin Immunol
NIH Public Access Author Manuscript Curr Opin Immunol. Author manuscript; available in PMC 2012 April 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Curr Opin Immunol. 2011 April ; 23(2): 198±206. doi:10.1016/j.coi.2010.11.007. Aire and T cell Development Mark S. Andersona,* and Maureen A. Sub,* a Diabetes Center and Department of Medicine, University of California, San Francisco, San Francisco, CA b Inflammatory Diseases Institute and Department of Pediatrics, University of North Carolina, Chapel Hill, Chapel Hill, NC Abstract In the thymus, developing T cells that react against self-antigens with high affinity are deleted in the process of negative selection. An essential component of this process is the display of self- antigens, including those whose expression are usually restricted to specific tissues, to developing T cells within the thymus. The Autoimmune Regulator (Aire) gene plays a critical role in the expression of tissue specific self-antigens within the thymus, and disruption of Aire function results in spontaneous autoimmunity in both humans and mice. Recent advances have been made in our understanding of how Aire influences the expression of thousands of tissue-specific antigens in the thymus. Additional roles of Aire, including roles in chemokine and cytokine expression, have also been revealed. Factors important in the differentiation of Aire-expressing medullary thymic epithelial cells have been defined. Finally, the identity of antigen presenting cells in negative selection, including the role of medullary thymic epithelial cells in displaying tissue specific antigens to T cells, has also been clarified. -
Crosstalk Between SOX2 and TGF-Β Signaling Regulates EGFR-TKI Tolerance and Lung Cancer Dissemination
Author Manuscript Published OnlineFirst on August 19, 2020; DOI: 10.1158/0008-5472.CAN-19-3228 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Crosstalk between SOX2 and TGF-β signaling regulates EGFR-TKI tolerance and lung cancer dissemination Ming-Han Kuo1,10, An-Chun Lee1,10, Shih-Hsin Hsiao2,10, Sey-En Lin3,4, Yu-Fan Chiu1, Li-Hao Yang1, Chia-Cherng Yu5, Shih-Hwa Chiou6,7, Hsien-Neng Huang8, Jen-Chung Ko9*, Yu-Ting Chou1* 1Institute of Biotechnology, National Tsing Hua University, Hsinchu, Taiwan; 2Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan; 3Department of Pathology, Taipei Medical University Hospital, Taipei, Taiwan; 4Department of Pathology, Taipei Municipal Wan Fang Hospital, Taipei, Taiwan; 5Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan; 6Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan; 7Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan; 8Department of pathology, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan; 9Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan;10Co-first authors *Corresponding authors Jen-Chung Ko, National Taiwan University Hospital, Hsin-Chu Branch, No. 25, Lane 442, Sec. 1, Jingguo Rd., Hsinchu 30013, Taiwan. E-mail: [email protected] Yu-Ting Chou, National Tsing Hua University, No. 101, Sec. 2, Kuang-Fu Rd., Hsinchu 30013, Taiwan. E-mail: [email protected] Running title: Interplay of SOX2 and TGF- on EGFR–TKI tolerance Conflicts of interest The authors disclose no potential conflicts of interest. This work was supported by National Tsing Hua University and Ministry of Science and Technology, Executive Yuan, Taiwan. -
Annual Report Fy 2018 Human Frontier Science Program Organization
APRIL 2017 APRIL 2018 — MARCH 2019 ANNUAL REPORT FY 2018 HUMAN FRONTIER SCIENCE PROGRAM ORGANIZATION The Human Frontier Science Program Organization (HFSPO) is unique, supporting international collaboration to undertake innovative, risky, basic research at the frontier of the life sciences. Special emphasis is given to the support and training of independent young investigators, beginning at the postdoctoral level. The Program is implemented by an international organisation, supported financially by Australia, Canada, France, Germany, India, Italy, Japan, the Republic of Korea, New Zealand, Norway, Singapore, Switzerland, the United Kingdom of Great Britain and Nothern Ireland, the United States of America, and the European Commission. Since 1990, over 7000 researchers from more than 70 countries have been supported. Of these, 28 HFSP awardees have gone on to receive the Nobel Prize. 2 The following documents are available on the HFSP website www.hfsp.org: Joint Communiqués (Tokyo 1992, Washington 1997, Berlin 2002, Bern 2004, Ottawa 2007, Canberra 2010, Brussels 2013, London 2016): https://www.hfsp.org/about/governance/membership Statutes of the International Human Frontier Science Program Organization: https://www.hfsp.org/about/governance/hfspo-statutes Guidelines for the participation of new members in HFSPO: https://www.hfsp.org/about/governance/membership General reviews of the HFSP (1996, 2001, 2006-2007, 2010, 2018): https://www.hfsp.org/about/strategy/reviews Updated and previous lists of awards, including titles and abstracts: -
Balancing Potency and Differentiation in Mouse Embryo-Derived Stem Cells and in Vivo
Balancing potency and differentiation in mouse embryo-derived stem cells and in vivo By Anne Christine Helness A thesis submitted to Imperial College London for the degree of Doctor of Philosophy Department of Surgery and Oncology Imperial College London September 2011 1 Abstract An inherent challenge for developing organisms is to maintain a critical balance between cell potency and differentiation. This is most obvious in embryonic stem (ES) cells where genetic, epigenetic and cell signalling pathways support ES cell ability to self-renew and to generate all embryonic lineages. Recently, a series of reports revealed how Polycomb-mediated repression might buffer the precocious expression of somatic lineage regulators in ES cells. Notably, these genes carry bivalent chromatin enriched in both repressive (H3K27me3) and permissive (H3K4me2) histone marks. They are targeted by the Polycomb repressive complexes PRC1 (Ring1B) and PRC2, which mediates H3K27me3 and assemble poised RNA polymerase II (RNAP II), conferring silencing of loci primed for future activation (or repression) upon ES cell differentiation. During early development the transition from morula to blastocyst is the starting point for lineage segregation into the inner cell mass (ICM) and trophectoderm (TE). ES cells are derived from the ICM and are pluripotent. By contrast, TE-derived trophoblast stem (TS) cells are multipotent and contribute solely to placenta formation in vivo. To address whether ES cells epigenetic features are unique attributes of pluripotent cells in the early embryo, we compared the epigenetic status of key developmental genes in blastocyst-derived stem cells and in vivo. We provide direct evidence that bivalent histone markings operate in vivo from the eight-cell up to the blastocyst stage. -
A Sox2 Distal Enhancer Cluster Regulates Embryonic Stem Cell Differentiation Potential
Downloaded from genesdev.cshlp.org on September 27, 2021 - Published by Cold Spring Harbor Laboratory Press A Sox2 distal enhancer cluster regulates embryonic stem cell differentiation potential Harry Y. Zhou,1,3 Yulia Katsman,1,3 Navroop K. Dhaliwal,1 Scott Davidson,1 Neil N. Macpherson,1 Moorthy Sakthidevi,1 Felicia Collura,1 and Jennifer A. Mitchell1,2 1Department of Cell and Systems Biology, University of Toronto, Toronto, Ontario M5S 3G5, Canada; 2Center for the Analysis of Genome Evolution and Function, University of Toronto, Toronto, Ontario M5S 3G5, Canada The Sox2 transcription factor must be robustly transcribed in embryonic stem (ES) cells to maintain pluripotency. Two gene-proximal enhancers, Sox2 regulatory region 1 (SRR1) and SRR2, display activity in reporter assays, but deleting SRR1 has no effect on pluripotency. We identified and functionally validated the sequences required for Sox2 transcription based on a computational model that predicted transcriptional enhancer elements within 130 kb of Sox2. Our reporter assays revealed three novel enhancers—SRR18, SRR107, and SRR111—that, through the formation of chromatin loops, form a chromatin complex with the Sox2 promoter in ES cells. Using the CRISPR/ Cas9 system and F1 ES cells (Mus musculus129 3 Mus castaneus), we generated heterozygous deletions of each enhancer region, revealing that only the distal cluster containing SRR107 and SRR111, located >100 kb downstream from Sox2, is required for cis-regulation of Sox2 in ES cells. Furthermore, homozygous deletion of this distal Sox2 control region (SCR) caused significant reduction in Sox2 mRNA and protein levels, loss of ES cell colony morphology, genome-wide changes in gene expression, and impaired neuroectodermal formation upon spontaneous differentiation to embryoid bodies. -
EMBO Encounters Issue43.Pdf
WINTER 2019/2020 ISSUE 43 Nine group leaders selected Meet the first EMBO Global Investigators PAGE 6 Accelerating scientific publishing EMBO publishing costs Review Commons Making our journals’ platform announced finances public PAGE 3 PAGES 10 – 11 Welcome, Young Investigators! Contract replaces stipend Marking ten years 27 group leaders join the programme EMBO Postdoctoral Fellowships EMBO Molecular Medicine receive an update celebrates anniversary PAGES 4 – 5 PAGE 7 PAGE 13 www.embo.org TABLE OF CONTENTS EMBO NEWS EMBO news Review Commons: accelerating publishing Page 3 EMBO Molecular Medicine turns ten © Marietta Schupp, EMBL Photolab Marietta Schupp, © Page 13 Editorial MBO was founded by scientists for Introducing 27 new Young Investigators scientists. This philosophy remains at Pages 4-5 Ethe heart of our organization until today. EMBO Members are vital in the running of our Meet the first EMBO Global programmes and activities: they screen appli- Accelerating scientific publishing 17 journals on board Investigators cations, interview candidates, decide on fund- Review Commons will manage the transfer of ing, and provide strategic direction. On pages EMBO and ASAPbio announced pre-journal portable review platform the manuscript, reviews, and responses to affili- Page 6 8-9 four members describe why they chose to ate journals. A consortium of seventeen journals New members meet in Heidelberg dedicate their time to an EMBO Committee across six publishers (see box) have joined the Fellowships: from stipends to contracts Pages 14 – 15 and what they took away from the experience. n December 2019, EMBO, in partnership with decide to submit their work to a journal, it will project by committing to use the Review Commons Page 7 When EMBO was created, the focus lay ASAPbio, launched Review Commons, a multi- allow editors to make efficient editorial decisions referee reports for their independent editorial deci- specifically on fostering cross-border inter- Ipublisher partnership which aims to stream- based on existing referee comments. -
O-Glcnac Modification of Oncogenic Transcription Factor Sox2 Promotes Protein Stability and Regulates Self-Renewal in Pancreatic Cancer
bioRxiv preprint doi: https://doi.org/10.1101/345223; this version posted June 12, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. O-GlcNAc modification of oncogenic transcription factor Sox2 promotes protein stability and regulates self-renewal in pancreatic cancer Nikita S Sharma1, Vineet K Gupta1, Patricia Dauer2, Kousik Kesh1, Roey Hadad1, Bhuwan Giri1, Anjali Chandra5, Vikas Dudeja1,4, Chad Slawson3, Santanu Banerjee1,4, Selwyn M Vickers6, Ashok Saluja1, 4 and Sulagna Banerjee1, 4* 1Department of Surgery, University of Miami, Miami, FL. 2Department of Pharmacology, University of Minnesota, Minneapolis Minnesota. 3University of Kansas Medical Center, Kansas City, KS. 4Sylvester Comprehensive Cancer Center, Miami, FL. 5 Department of Psychology, Harvard University. 6 School of Medicine Dean’s Office, University of Alabama at Birmingham. * Corresponding Author Address of Correspondence: 1550 NW 10th Ave Papanicolau Building, Suite 109B Miami, FL 33136 [email protected] (305)-243-8242 Running Title: O-GlcNAc modified Sox2 mediates self-renewal in PDAC Keywords: OGT, O-GlcNAc, Sox2, Pancreatic cancer, metabolism, self-renewal Financial Support This study was funded by NIH grants R01-CA170946 and R01-CA124723 (to AKS); NIH grant R01-CA184274 (to SB); Katherine and Robert Goodale foundation support (to AKS), Minneamrita Therapeutics LLC (to AKS). The authors would also like to acknowledge Oncogenomics Core at the Sylvester Cancer Center, University of Miami for their help with the RNA seq transcriptomics study. bioRxiv preprint doi: https://doi.org/10.1101/345223; this version posted June 12, 2018. -
Dr. Janet Rossant ANDREW F. HOLMES DEAN of MEDICINE DISTINCTION LECTURES
Dr. Janet Rossant ANDREW F. HOLMES DEAN OF MEDICINE DISTINCTION LECTURES Dr. Janet Rossant, PhD, FRS, FRSC Chief of Research, SickKids Senior Scientist, Developmental & Stem Cell Biology, SickKids Lombard Insurance Chair in Pediatric Research University Professor, Department of Molecular Genetics, Obstetrics and Gynecology, University of Toronto Title Stem cells and early lineage development When Friday, October 18, 2013 11:30 a.m. – 1:00 p.m. Where CP Leblond Amphitheatre Strathcona Anatomy and Dentistry Building 3640 rue University Montreal, QC H3G 1Y6 Dr. Janet Rossant, SickKids Chief of Research and a world-renowned expert in developmental biology, is the definition of a trailblazer. Widely known for her studies of the genes that control embryonic development in the mouse, Dr. Rossant has pioneered techniques for following cell fate and altering genes in embryos. This work continues to resonate in medical genetic research. Her current research focuses on stem cell development and cell differentiation in the developing embryo, important areas for the study of birth defects as well as regenerative medicine. Firmly planted on the front lines of technological change, Dr. Rossant has established SickKids as a global forerunner in genetic research. Janet Rossant was born in Chatham, UK, and trained at the Universities of Oxford and Cambridge, United Kingdom. In 1977, Dr. Rossant moved to Canada and joined the faculty at Brock University. From 1985 to 2005, she was a leading researcher at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto. She joined SickKids in 2005 and became Chief of Research of the Research Institute. She is also a University Professor at the University of Toronto.